The Course of Covid-19 in Arterial Hypertension and Evaluate the Effectiveness in Diagnosis

dc.creatorB. M., Tadjiev
dc.creatorA. M, Khusanov
dc.creatorSh. A., Khasanova
dc.creatorA. X., Nurmatov
dc.creatorSh., Xaliqova
dc.date2023-02-14
dc.date.accessioned2023-08-21T09:04:26Z
dc.date.available2023-08-21T09:04:26Z
dc.descriptionCardiovascular disease (CVD) is considered the leading cause of death worldwide, and none other than these is the leading cause of death each year. An estimated 17.9 million people died of CVD in 2016, accounting for 31% of all deaths worldwide. 85% of these deaths were caused by heart attacks and strokes. More than 75% of deaths occur in low- or middle-income countries. 17 million deaths from noncommunicable diseases were observed under the age of 70, with 82% of cases occurring in low- and middle-income countries, of which 37% were due to CVD. According to the World Health Organization (WHO), the number of deaths from CVD in 2019 increased by almost 2 million compared to 2000. Patients with CVD and the associated risk factor, hypertension, are reported to be at greater risk of developing COVID-19 and adverse outcomes due to COVID-19. To reduce the negative impact on the health and economy of the European Region, effective control of CVD is recommended.en-US
dc.formatapplication/pdf
dc.identifierhttps://univerpubl.com/index.php/scholastic/article/view/365
dc.identifier.urihttp://dspace.umsida.ac.id/handle/123456789/21868
dc.languageeng
dc.publisherUniver Publishingen-US
dc.relationhttps://univerpubl.com/index.php/scholastic/article/view/365/295
dc.sourceScholastic: Journal of Natural and Medical Education; Vol. 2 No. 2 (2023): Scholastic: Journal of Natural and Medical Education; 177-194en-US
dc.subjectCovid-19en-US
dc.titleThe Course of Covid-19 in Arterial Hypertension and Evaluate the Effectiveness in Diagnosisen-US
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typePeer-reviewed Articleen-US
Files